ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 10, 2018
Omega’s First-Quarter Results Not Terrible; Dividend Still Intact
Image Source: Omega Healthcare, March 2018 presentation. Omega Healthcare is a healthcare real estate investment trust (REIT) that has been battling concerns within its customer base regarding rent payments. Just how healthy its customer line-up truly is will likely play out in coming years, but for now, management is leaving the dividend intact. Shares yield 9%+ at the time of this writing.
May 10, 2018
Soft Guidance Weighs on Booking Holdings Despite Solid First Quarter
Image Source: Luca Conti. You may have read this sentiment before: shares of Booking Holdings, formerly Priceline, are facing pressure following a solid quarterly report as management continued its habit of issuing conservative quarterly guidance.
May 10, 2018
Generic Drug Deflation Continues to Hamper Cardinal Health and AmerisourceBergen
Image Source: Aaron Fulkerson. A severe case of rampant generic drug deflation continues to hamper the share prices of Cardinal Health and AmerisourceBergen. We are monitoring the drug deflation numbers posted by the drug wholesalers as a key gauge of the investment merits of the group.
May 9, 2018
Realty Income Occupancy Highest in More Than a Decade
Image Source: Realty Income. Simulated Dividend Growth Newsletter portfolio idea Realty Income delivered a solid first quarter 2018 report that included impressive occupancy rates, steady adjusted funds from operations growth, and ongoing dividend expansion.
May 4, 2018
Dividend Increases/Decreases for the Week Ending May 4
Let's take a look at companies that raised/lowered their dividend this week.
May 3, 2018
Gilead Sciences at the Crossroads; HIV and Oncology Franchises Promising
Image Source: Gilead Sciences' first-quarter 2018 results. The loss of a key revenue-generating molecule is a tough, yet oftentimes manageable, portion of a pharma entity’s overall life cycle. Gilead Sciences is in the midst of a key turnaround as the loss of revenue from its Hepatitis C franchise is beginning to abate, while new novel treatments embark on the early stages of their respective revenue cycles. That said, we'd like to see traction in its HIV and oncology franchises, and perhaps the addition of a new franchise to the portfolio, or we will sour on the stock long-term.
May 3, 2018
Oil Majors Benefit from Higher Energy Resource Prices
Exxon Mobil, ConocoPhillips, and Chevron reported improved earnings and cash flow during the first quarter of 2018, thanks largely to higher realized energy resource pricing. The group may be better positioned for further bottom-line expansion moving forward as volume growth is expected to continue over the course of the year.
May 3, 2018
Growth Continues at Bristol-Myers; Eliquis Fantastic
Image Source: Bristol-Myers. Bristol Myers Squibb continues to put up nice revenue growth as demand for Eliquis is coming in better than expectations. The company’s hopes to win first-line therapy in combination therapy for non-small cell lung cancer with Opdivo have been dealt a severe blow, however. We haven’t liked Bristol-Myers' share-price performance of late and remain on the sidelines. However, we are watching its equity closely for addition to the simulated newsletter portfolios.
May 2, 2018
Waste Industry Collecting Cash
Pressures in the recycling business didn’t negate revenue growth across the municipal solid waste space during the first quarter of 2018, and the pace of operating-income and free-cash-flow expansion remains solid. Valuations could be more attractive, but dividends look strong, even though we’d like to see lower levels of financial leverage.
May 2, 2018
Apple’s Quarter Brings a Bushel of Positive News
Image Source: Aaron Yoo. Apple’s strength was on full display in its second quarter of fiscal 2018 as it beat expectations on a number of quarterly measures and delivered a significant dividend increase. The company remains one of our favorites on the market today. Our fair value estimate currently sits at $201 per share.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.